P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

Dettagli Bibliografici
Autori principali:	Lene Kongsgaard Nielsen, Fredrik Schjesvold, Sören Möller, Nina Guldbrandsen, Markus Hansson, Kari Remes, Valdas Pečeliūnas, Henrik Gregersen, Madeleine King, Niels Abildgaard
Natura:	Articolo
Lingua:	English
Pubblicazione:	Wiley 2023-08-01
Serie:	HemaSphere
Accesso online:	http://journals.lww.com/10.1097/01.HS9.0000973556.03778.92

Documenti analoghi

Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group
di: Lene Kongsgaard Nielsen, et al.
Pubblicazione: (2024-02-01)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
di: Marcelo Capra, et al.
Pubblicazione: (2021-10-01)

P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.
di: David H. Vesole, et al.
Pubblicazione: (2023-08-01)

Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma—A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone
di: Tobias S. Slørdahl, et al.
Pubblicazione: (2025-02-01)

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
di: H. Quach, et al.
Pubblicazione: (2022-06-01)

P893: CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS: ITALIAN, MULTICENTER, RETROSPECTIVE EXPERIENCE OUTSIDE OF CLINICAL TRIALS
di: E. A. Martino, et al.
Pubblicazione: (2022-06-01)

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
di: Giuseppe Mele, et al.
Pubblicazione: (2018-01-01)

The third Earl of Shaftesbury (1671-1713)
di: Cunliffe, C, et al.
Pubblicazione: (1981)

P938: CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE CONSOLIDATION IN MYELOMA PATIENTS WITH A POSITIVE FDG PET/CT AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION: A PHASE II STUDY (CONPET)
di: J. N. Nørgaard, et al.
Pubblicazione: (2022-06-01)

Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
di: Yi L, et al.
Pubblicazione: (2024-11-01)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
di: Pieter Sonneveld, et al.
Pubblicazione: (2022-10-01)

P950: COMBINED PROTEASOME AND AUTOPHAGY INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A PHASE I TRIAL OF HYDROXYCHLOROQUINE, CARFILZOMIB AND DEXAMETHASONE
di: T. S. Slørdahl, et al.
Pubblicazione: (2022-06-01)

Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
di: Dominik Dytfeld, et al.
Pubblicazione: (2014-09-01)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
di: Xavier Leleu, et al.
Pubblicazione: (2023-02-01)

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
Pubblicazione: (2023-03-01)

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report
di: Reilly Fankhauser, et al.
Pubblicazione: (2024-11-01)

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
di: Manisha Bhutani, et al.
Pubblicazione: (2025-02-01)

Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient
di: Sarolta Bojtine Kovacs, et al.
Pubblicazione: (2020-03-01)

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma
di: Elisabet E. Manasanch, et al.
Pubblicazione: (2020-05-01)

Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma
di: Deborah Osafehinti, et al.
Pubblicazione: (2019-01-01)

Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma
di: Juan José Gil‐Fernández, et al.
Pubblicazione: (2024-01-01)

Carfilzomib induced Alveolar Hemorrhage
di: Zachary Holtzapple, et al.
Pubblicazione: (2023-12-01)

Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysis
di: Thierry Facon, et al.
Pubblicazione: (2023-08-01)

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
di: Roberto Mina, et al.
Pubblicazione: (2020-02-01)

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
di: Benjamin A. Derman, et al.
Pubblicazione: (2024-05-01)

The negotiations: hampered by the UK's weak strategy
di: Jones, E
Pubblicazione: (2019)

Hybrid adaptation is hampered by Haldane’s sieve
di: Carla Bautista, et al.
Pubblicazione: (2024-11-01)

P1671: GENES POLYMORPHISM OF THROMBOPHILIA AND PROTHROMBOTIC CONDITIONS IN WOMEN WITH VARIOUS OBSTETRIC ANAMNESIS
di: A. Zagarskikh, et al.
Pubblicazione: (2022-06-01)

Missionary Writings during the Canton Exile (1666–1671): Crisis in the Manchu-Christian Relationship
di: Thierry Meynard
Pubblicazione: (2024-02-01)

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)
di: Kwee L. Yong, et al.
Pubblicazione: (2021-04-01)

Peter A. Mazur, The New Christians of Spanish Naples, 1528-1671: A Fragile Elite
di: José Alberto Tavim
Pubblicazione: (2014-12-01)

Lack of data hampering early flood warning
di: Jalil, Haikal
Pubblicazione: (2014)

Economic headlines: Supply bottlenecks hamper production
di: Joscha Beckmann, et al.
Pubblicazione: (2021-07-01)

Carbon dioxide hampers nitrate incorporation by plants
di: California Agriculture
Pubblicazione: (2002-05-01)

Misconceptions and misunderstandings hampering medical research and progress
di: Carmen Carazo-Díaz, et al.
Pubblicazione: (2024-08-01)

Carbon dioxide hampers nitrate incorporation by plants
Pubblicazione: (2002-05-01)

Factors hampering the implementation of gender equality in the workplace
di: Debbie Jansen, et al.
Pubblicazione: (2023-12-01)

Are improper kinetic models hampering drug development?
di: Ryan Walsh
Pubblicazione: (2014-10-01)

Рада старшины Левобережного Гетманства в Батурине в мае 1671 г. и ее решения
di: Борис Николаевич Флоря
Pubblicazione: (2021-06-01)

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
di: Ruth Wester, et al.
Pubblicazione: (2019-11-01)